DBV Technologies Secures $229M Cash Runway to Q2 2027, Eyes BLA Filings
DBV Technologies held $229 million cash as of March 31, 2026, funding operations into Q2 2027 after exercise of ABSA and BS warrants. Net loss widened to $47.6 million in Q1 from $27.1 million, while loss per share improved to $0.11, reflecting financing strength and ramped R&D and commercial preparations.
1. First Quarter Financial Results
DBV Technologies reported a net loss of $47.6 million for the three months ended March 31, 2026, compared with $27.1 million a year earlier. Loss per share narrowed to $0.11 from $0.26 on a strengthened equity base following recent financings.
2. Expense Increase Drivers
R&D expenses rose by $12 million year-over-year, driven by recruitment for COMFORT Toddlers, the VITESSE open-label extension, BLA-readiness activities, U.S. medical affairs investments and pre-commercial inventory build-up. SG&A costs increased by $9 million as the company builds its U.S. commercial infrastructure for a potential VIASKIN® Peanut Patch launch.
3. Strong Cash Position and Runway
Cash and equivalents totaled $229 million at quarter end, up from $194 million at December 31, 2025, supported by $89 million in financing from warrant exercises. Net cash used in operations was $49 million, giving a projected funding runway into the second quarter of 2027.
4. Upcoming Regulatory and Trial Milestones
The company plans BLA submissions for the VIASKIN® Peanut Patch in children aged 4-7 in H1 2026 and ages 1-3 in H2 2026. It will also launch the THRIVE Phase 2 study in peanut-allergic infants aged 6-12 months to assess long-term efficacy and safety after three years of treatment.